The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma
Table 2
Distribution of cases and controls, odds ratiosa (OR), and 95% confidence intervals (CI) for hepatocellular carcinoma (HCC) according to selected polymorphisms.
HCC cases ()
Controls ()
OR (95% CI)
(%)
(%)
CYP1A12A
wt/wt
165
(74.7)
226
(77.9)
1b
wt/mt and mt/mt
56
(25.3)
64
(22.7)
1.21 (0.80–1.84)
CYP2E15B
217
(98.2)
270
(93.1)
1b
and
4
(1.8)
20
(6.9)
0.23 (0.06–0.71)
CYP2E16
wt/wt
204
(99.0)
261
(90.0)
1d
wt/mt and mt/mt
2
(1.0)
29
(10.0)
0.08 (0.01–0.33)
GSTM1
Present
96
(47.8)
139
(48.1)
1b
Null
105
(52.2)
150
(51.9)
0.99 (0.68–1.43)
GSTT1
Present
141
(70.1)
220
(76.1)
1b
Null
60
(29.9)
69
(23.9)
1.35 (0.89–2.05)
SULT1A1
wt/wt
132
(59.7)
180
(62.1)
1b
wt/mt and mt/mt
89
(40.3)
110
(37.9)
1.22 (0.84–1.77)
Adjusted for age and sex.
bReference category.
cThe sum does not add up to the total because of some missing values.
dCalculated from exact logistic regression analysis. wt: wild-type allele. mt: variant-type allele.
